<DOC>
	<DOCNO>NCT00677079</DOCNO>
	<brief_summary>The goal study determine efficacy iniparib ( BSI-201/SAR240550 ) patient breast cancer gene-associated ( BRCA ) ovarian cancer . Up 35 patient treat use Simon 2-stage optimal design , i.e . twelve treat first stage , 2/12 patient respond treatment define Response Evaluation Criteria Solid Tumor ( RECIST ) , 23 additional patient treat second stage .</brief_summary>
	<brief_title>Single Arm Study BSI-201 Patients With BRCA-1 BRCA-2 Associated Advanced Epithelial Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>Participants treat least one 8-week cycle , additional cycle long stable respond disease ( per RECIST criterion ) wish remain study . Participants final follow-up visit within 4 week follow last dose iniparib , time contact study staff every 3 month first year every 6 month thereafter assess disease status survival .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<criteria>Female , age 18 old ; Histologically cytologically confirm advanced epithelial ovarian cancer , fallopian tube cancer primary peritoneal cancer ( stage III IV ) ; At least one previous regimen platinum/taxane combination therapy curative option determine physician ( limit number prior therapy ) ; Confirmed BRCA1 BRCA2 status ; One measurable lesion , least 10mm long diameter spiral compute tomography ( CT ) scan 20mm long diameter measure conventional technique ( palpation , plain xray , CT magnetic resonance imaging ( MRI ) ) ; Karnofsky performance status â‰¥70 % ; Estimated life expectancy least 16 week . Normal clinical laboratory value ; Any anticancer therapy within 21 day prior study start ; Any malignancy within 3 year study start , except adequately treat carcinoma situ cervix , ductal carcinoma situ ( DCIS ) breast , basal squamous cell skin cancer ; Active viral infection include HIV/AIDS , Hepatitis B Hepatitis C infection ; Active central nervous system brain metastasis ; History seizures current treatment antiepileptic medication ; Persistent grade 2 great toxicity prior therapy , exclude alopecia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>BRCA-1 BRCA-2 associate advanced epithelial ovarian , fallopian tube , primary peritoneal cancer</keyword>
	<keyword>BRCA-1</keyword>
	<keyword>BRCA-2</keyword>
</DOC>